Bank of New York Mellon Corp Reduces Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Bank of New York Mellon Corp lowered its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 3.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 385,501 shares of the specialty pharmaceutical company’s stock after selling 14,083 shares during the quarter. Bank of New York Mellon Corp owned about 0.69% of Supernus Pharmaceuticals worth $12,625,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of SUPN. Raiffeisen Bank International AG purchased a new position in shares of Supernus Pharmaceuticals in the fourth quarter worth $25,000. Financial Management Professionals Inc. purchased a new position in Supernus Pharmaceuticals in the 1st quarter worth $30,000. Versant Capital Management Inc lifted its position in Supernus Pharmaceuticals by 6,931.3% during the 1st quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company’s stock worth $37,000 after acquiring an additional 1,109 shares during the period. GF Fund Management CO. LTD. acquired a new stake in Supernus Pharmaceuticals during the 4th quarter worth about $42,000. Finally, Mark Sheptoff Financial Planning LLC purchased a new stake in Supernus Pharmaceuticals during the 4th quarter valued at about $52,000.

Supernus Pharmaceuticals Price Performance

NASDAQ SUPN opened at $32.34 on Monday. The company has a fifty day moving average of $32.41 and a 200 day moving average of $33.62. The company has a market capitalization of $1.81 billion, a PE ratio of 29.14 and a beta of 0.70. Supernus Pharmaceuticals, Inc. has a 1 year low of $27.05 and a 1 year high of $40.28.

Analyst Ratings Changes

Separately, Wall Street Zen cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.